In contrast to the first two reports suggesting the functions of FcRγ ITAM tyrosines, recent mouse studies revealed that daratumumab, which is a monoclonal therapeutic antibody targeting CD38 that is highly expressed on the surface of some kinds of tumor cells, induces cancer cell death after its binding, which process occurs in NOTAM but not in FcRγ-deficient mice after blocking FcγRIIB (19). Here, FCER1G is linked to cancer.